A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: Correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features

Trigka,Eleni  Andriana; Levidou,Georgia; Saetta,Angelica  A.; Chatziandreou,Ilenia; Tomos,Periklis; Thalassinos,Nikolaos; Anastasiou,Nikolaos; Spartalis,Eleftherios; Kavantzas,Nikolaos; Patsouris,Efstratios; Korkolopoulou,Penelope

doi:10.3892/or.2013.2512

A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: Correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features

Authors:
- Eleni Andriana Trigka
- Georgia Levidou
- Angelica A. Saetta
- Ilenia Chatziandreou
- Periklis Tomos
- Nikolaos Thalassinos
- Nikolaos Anastasiou
- Eleftherios Spartalis
- Nikolaos Kavantzas
- Efstratios Patsouris
- Penelope Korkolopoulou
View Affiliations

Affiliations: First Department of Pathology, University of Athens Medical School, Laiko General Hospital, 11527 Athens, Greece, Second Department of Propaedeutic Surgery, University of Athens Medical School, Laiko General Hospital, 11527 Athens, Greece, Department of Thoracic Surgery, 1st IKA Hospital, 15127 Athens, Greece
Published online on: May 31, 2013 https://doi.org/10.3892/or.2013.2512
Pages: 623-636

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The phosphoinositide 3-kinase (PI3K)/v-akt murine thymoma viral oncogene homolog (AKT)/mammalian target of rapamycin (mTOR) pathway is upregulated in a number of human cancers, including non-small cell lung cancer (NSCLC). Its potential role in NSCLC progression provides an attractive target for anticancer therapy. The expression of phosphorylated mTOR (p-mTOR), phosphorylated AKT (p-AKT), p85α and p110γ subunits of PI3K, phosphorylated p70S6K (p-p70S6K), phosphatase and tensin homolog (PTEN) and phosphorylated 4E-BP1 (p‑4E‑BP1) was examined by immunohistochemistry in 102 NSCLC specimens. The results were correlated with clinicopathological features. We also examined 61 of our cases for the presence of PIK3CA, AKT1, PTEN and K-RAS mutations. A common PIK3CA mutation was detected at exon 9 in 2 samples (p.E545K), whereas another sample displayed a rare mutation (p.D1018N). Furthermore, 10 out of 54 cases (18.5%) had a K-RAS mutation at codon 12, 5 had a PTEN mutation (exons 7 and 8) and 1 case had an AKT1 mutation (p.E17K). PTEN mutations were associated with nodal metastases. The expression of p-mTOR positively correlated with that of p-AKT and p-p70S6K and was higher in adenocarcinomas along with nuclear p110γPI3K expression, whereas p-4E-BP1 expression was higher in squamous cell carcinomas. We also established a positive association between p85αPI3K or p110γPI3K and cytoplasmic p-AKT and its downstream effectors. An inverse correlation was noted between p-4E-BP1 immunoexpression and tumour status and nuclear p-AKT expression as regards tumour stage. Univariate survival analysis demonstrated that p-4E-BP1 expression, either alone or in combination with cytoplasmic p-AKT expression had an adverse prognostic significance in adenocarcinomas. The combination of p-4E‑BP1 and cytoplasmic p-AKT expression remained significant in the multivariate analysis as a function of their interaction with histological type. Our data demonstrate the significance of p‑4E‑BP1 immunoexpression as a molecular marker of prognostic value in adenocarcinomas, particularly when combined with p-AKT.

View Figures

View References

1	Travis WD; IASLC Staging Committee. Reporting lung cancer pathology specimens. Impact of the anticipated 7th edition TNM classification based on recommendations of the IASLC Staging Committee. Histopathology. 54:3–11. 2009. View Article : Google Scholar : PubMed/NCBI
2	Jemal A, Siegel R, Ward E, et al: Cancer statistics: 2007. CA Cancer J Clin. 57:43–66. 2007. View Article : Google Scholar
3	Vivanco I and Sawyers CL: The phosphatidyloinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer. 2:489–501. 2002. View Article : Google Scholar : PubMed/NCBI
4	Sarbassov DD, Ali SM and Sabatini DM: Growing roles for the mTOR pathway. Curr Opin Cell Biol. 17:596–603. 2005. View Article : Google Scholar : PubMed/NCBI
5	Sarbassov DD, Ali SM, Kim DH, et al: Rictor, a novel binding pattern of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol. 14:1296–1302. 2004. View Article : Google Scholar : PubMed/NCBI
6	Hay N and Sonenberg N: Upstream and downstream of mTOR. Genes Dev. 18:1926–1945. 2004. View Article : Google Scholar
7	Gingras AC, Gypi SP, Raught B, et al: Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism. Genes Dev. 13:1422–1437. 1999. View Article : Google Scholar : PubMed/NCBI
8	Bjornsti MA and Houghton PJ: The TOR pathway: a target for cancer therapy. Nat Rev Cancer. 4:335–348. 2004. View Article : Google Scholar : PubMed/NCBI
9	Yu J, Zhang Y, McIlroy J, et al: Regulation of the p85/p110 phosphstidyloinositol 3′-kinase: stabilization and inhibition of the p110alpha catalytic subunit by the p85 regulatory subunit. Mol Cell Biol. 18:1379–1387. 1998.
10	Miled N, Yan Y, Hon WC, et al: Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit. Science. 317:239–242. 2007. View Article : Google Scholar : PubMed/NCBI
11	Yamamoto H, Hisayuki S, Masaharu N, et al: PI3KCA mutations and copy number gains in human lung cancer. Cancer Res. 68:693–621. 2008. View Article : Google Scholar
12	Scrima M, De Marco C, Fabiani F, et al: Signaling networks associated with AKT activation in non-small cell lung cancer (NSCLC): new insights on the role of phosphatidyl-inositol-3 kinase. PLoS One. 7:e304272012. View Article : Google Scholar : PubMed/NCBI
13	Marti A and Felip E: PI3K pathway in NSCLC. Front Oncol. 1:552012.
14	Stambolic V, Suzuki A, de la Pompa JL, et al: Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell. 95:29–39. 1998. View Article : Google Scholar : PubMed/NCBI
15	Wangpaichitr M, Wu C, You M, et al: Inhibition of mTOR restores cisplatin sensitivity through down-regulation of growth and anti-apoptotic proteins. Eur J Pharmacol. 591:124–127. 2008. View Article : Google Scholar : PubMed/NCBI
16	Balsara BR, Pei J, Mitsuuchi Y, et al: Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions. Carcinogenesis. 25:2053–2059. 2004. View Article : Google Scholar : PubMed/NCBI
17	Okudela K, Suzuki M, Kageyama S, et al: PIK3CA mutation and amplification in human lung cancer. Pathol Int. 57:664–671. 2007. View Article : Google Scholar : PubMed/NCBI
18	Yoshizawa A, Fukuoka J, Shimizu S, et al: Overexpression of phospho-eIF4E is associated with survival through AKT pathway in non-small cell lung cancer. Clin Cancer Res. 16:240–248. 2010. View Article : Google Scholar : PubMed/NCBI
19	Anagnostou VK, Bepler G, Syrigos KN, et al: High expression of mammalian target of rapamycin is associated with better outcome for patients with early stage lung adenocarcinoma. Clin Cancer Res. 15:4157–4164. 2009. View Article : Google Scholar : PubMed/NCBI
20	Tang JM, He QY, Guo RX, et al: Phosphorylated AKT overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis. Lung Cancer. 51:181–191. 2006. View Article : Google Scholar : PubMed/NCBI
21	Liu D, Huang Y, Chen B, et al: Activation of mammalian target of rapamycin pathway confers adverse outcome in nonsmall cell lung carcinoma. Cancer. 117:3763–3673. 2011. View Article : Google Scholar : PubMed/NCBI
22	Dobashi Y, Suzuki S, Matsubara H, et al: Critical and diverse involvement of Akt/mammalian target of rapamycin signaling in human lung carcinomas. Cancer. 115:107–118. 2009. View Article : Google Scholar : PubMed/NCBI
23	McDonald JM, Pelloski CE, Ledoux A, et al: Elevated phospho-S6 expression is associated with metastasis in adenocarcinoma of the lung. Clin Cancer Res. 14:7832–7837. 2008. View Article : Google Scholar : PubMed/NCBI
24	Khoury T, Alrawi S, Ramnath N, et al: Eukaryotic initiation factor-4E and cyclin D1 expression associated with patient survival in lung cancer. Clin Lung Cancer. 10:58–66. 2009. View Article : Google Scholar : PubMed/NCBI
25	Wang R, Genng J, Wang JH, et al: Overexpression of eukaryotic initiation factor 4E (eIF4E) ad its clinical significance in lung adenocarcinoma. Lung Cancer. 66:237–244. 2009. View Article : Google Scholar : PubMed/NCBI
26	Oh MH, Lee HJ, Yoo SB, et al: Clinicopathological correlations of mTOR and pAkt expression in non-small cell lung cancer. Virchows Arch. 460:601–609. 2012. View Article : Google Scholar : PubMed/NCBI
27	Zito CR, Jilaveanu LB, Anagnostou V, et al: Multi-level targeting of the phosphatidyloinositol-3-kinase pathway in non-small cell lung cancer cells. PLoS One. 7:e313312012. View Article : Google Scholar : PubMed/NCBI
28	Gately K, Al-Alao B, Dhillon T, et al: Overexpression of the mammalian target of rapamycin (mTOR) and angioinvasion are poor prognostic factors in early stage NSCLC: a verification study. Lung Cancer. 75:217–222. 2012. View Article : Google Scholar : PubMed/NCBI
29	Dhillon T, Mauri FA, Belezza G, et al: Overexpression of the mammalian target of rapamycin: a novel biomarker for poor survival in resected early stage non-small cell lung cancer. J Thorac Oncol. 5:314–319. 2010. View Article : Google Scholar : PubMed/NCBI
30	Lim WT, Zhang WH, Miller CR, et al: PTEN and phosphorylated AKT expression and prognosis in early- and late-stage non-small cell lung cancer. Oncol Rep. 17:853–857. 2007.PubMed/NCBI
31	Shi Y, Chen L, Li J, et al: Prognostic and predictive values of pERK1/2 and pAkt-1 expression in non-small cell lung cancer patients treated with adjuvant chemotherapy. Tumour Biol. 32:381–389. 2011. View Article : Google Scholar : PubMed/NCBI
32	David O, Jett J, LeBeau H, et al: Phospho-Akt overexpression in non-small cell lung cancer confers significant stage-independent survival disadvantage. Clin Cancer Res. 10:6865–6871. 2004. View Article : Google Scholar
33	Korkolopoulou P, Levidou G, Trigka EA, et al: A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma. BJU Int. E1237–E1248. 2012. View Article : Google Scholar
34	Levidou G, Saetta AA, Gigelou F, et al: ERK/pERK expression and B-raf mutations in colon adenocarcinomas: correlation with clinicopathological characteristics. World J Surg Oncol. 10:472012. View Article : Google Scholar : PubMed/NCBI
35	Rojo F, Najera L, Lirola J, et al: 4E-binding protein 1, a cell signaling hallmark in breast cancer that correlates with pathologic grade and prognosis. Clin Cancer Res. 13:81–89. 2007. View Article : Google Scholar : PubMed/NCBI
36	Fujisaka Y, Yamada Y, Yamamoto N, et al: A phase 1 clinical study of temsirolimus (CCI-779) in Japanese patients with advanced solid tumors. Jpn J Clin Oncol. 40:732–738. 2010. View Article : Google Scholar : PubMed/NCBI
37	Pal SK, Figlin RA and Reckamp KL: The role of targeting mammalian target of rapamycin in lung cancer. Clin Lung Cancer. 9:340–345. 2008. View Article : Google Scholar : PubMed/NCBI
38	An SJ, Chen ZH, Su J, et al: Identification of enriched driver gene alterations in subgroups of non-small cell lung cancer patients based on histology and smoking status. PLoS One. 7:e401092012. View Article : Google Scholar : PubMed/NCBI
39	Thomas G: The S6 kinase signaling pathway in the control of development and growth. Biol Res. 35:305–313. 2002. View Article : Google Scholar : PubMed/NCBI
40	Riemenschneider MJ, Betensky RA, Pasedag SM, et al: AKT activation in human glioblastomas enhances proliferation via TSC1 and S6 kinase signaling. Cancer Res. 66:5618–5623. 2006. View Article : Google Scholar : PubMed/NCBI
41	Han S, Khuri FR and Roman J: Fibronectin stimulates non-small cell lung cancinoma cell growth through activation of Akt/mammalian target of rapamycin/S6 kinase and inactivation of LKB1/AMP-activated protein kinase signal pathways. Cancer Res. 66:315–323. 2006. View Article : Google Scholar : PubMed/NCBI
42	Johnson SM, Gulhati P, Rampy BA, et al: Novel expression patterns of PI3K/Akt/mTOR signaling pathway components in colorectal cancer. J Am Coll Surg. 210:767–778. 2010. View Article : Google Scholar : PubMed/NCBI
43	Bose S, Chandran S, Mirocha JM and Bose N: The Akt pathway in human breast cancer: a tissue-array-based analysis. Mod Pathol. 19:238–245. 2009. View Article : Google Scholar : PubMed/NCBI
44	Pantuck AJ, Seligson DB, Klatte T, et al: Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy. Cancer. 109:2257–2267. 2007. View Article : Google Scholar : PubMed/NCBI
45	Sun CH, Chang YH and Pan CC: Activation of the PI3K/Akt/mTOR pathway correlates with tumour progression and reduced survival in patients with urothelial carcinoma of the urinary bladder. Histopathology. 58:1054–1063. 2011. View Article : Google Scholar : PubMed/NCBI
46	Liliental J, Moon SY, Lesche R, et al: Genetic deletion of the Pten tumor suppressor gene promotes cell motility by activation of Rac1 and Cdc42 GTPases. Curr Biol. 10:401–404. 2000. View Article : Google Scholar : PubMed/NCBI
47	Dai B, Kong YY, Ye DW, et al: Activation of the mammalian target of rapamycin signaling pathway in prostate cancer and its association with patient clinicopathological characteristics. BJU Int. 104:1009–1016. 2009. View Article : Google Scholar : PubMed/NCBI
48	Seki N, Takasu T, Mandai K, et al: Expression of eukaryotic initiation factor 4E in atypical adenomatous hyperplasia and adenocarcinoma of the human peripheral lung. Clic Cancer Res. 8:3046–3053. 2002.PubMed/NCBI
49	Rosenwald IB, Hutzler MJ, Wang S, et al: Expression of eukaryotic translation initiation factors 4E and 2alpha is increased frequently in bronchioalveolar but not in squamous cell carcinomas of the lung. Cancer. 92:2164–2171. 2001. View Article : Google Scholar : PubMed/NCBI
50	Sun SY, Rosenberg LM, Wang X, et al: Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res. 65:7052–7058. 2005. View Article : Google Scholar : PubMed/NCBI
51	Armengol G, Rojo F, Castellvi J, et al: 4E-binding protein 1: a key molecular ‘funnel factor’ in human cancer with clinical implications. Cancer Res. 67:7551–7555. 2007.
52	Dumstorf CA, Konicek BW, McNulty AM, et al: Modulation of 4E-BP1 function as a critical determinant of enzastaurin-induced apoptosis. Mol Cancer Ther. 9:3158–3163. 2010. View Article : Google Scholar : PubMed/NCBI